Recursion plans to present updated data from the TUPELO trial in an upcoming webinar scheduled for December 8, 2025. This presentation will provide further insights into the drug’s safety and efficacy ...
Hosted on MSN
Recursion Pharmaceuticals reports positive Phase 1b/2 TUPELO trial results, validating AI-driven therapy for FAP
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results